Parker Acquires Exoskeleton Technology Rights

CLEVELAND /PRNewswire/ -- Parker Hannifin Corp., a global leader in motion and control technologies, announced that it has signed an exclusive licensing agreement with Vanderbilt University for its exoskeleton technology, which allows individuals with severe spinal cord injury to walk and enhances rehabilitation of people who have suffered a stroke. The agreement gives Parker exclusive rights to develop, manufacture, and sell the device. Parker intends to invest in further development of the technology and establish a business unit targeting commercial launch of the exoskeleton in 2014.

"This agreement offers Parker an exciting growth opportunity in the area of biomechanics," said Craig Maxwell, Vice President of Technology and Innovation for Parker. "By leveraging our core motion and control technology, we are confident that we can take the company in new and exciting directions while improving the lives of people who experience mobility challenges. Having studied the current state of the art, we believe the technology developed at Vanderbilt is far superior in terms of both design and functional performance. We are embarking on an aggressive development and launch plan to bring what was once thought of as science fiction into the marketplace."

The Parker exoskeleton offers numerous advantages over existing technologies being tested in rehabilitation clinics. The exoskeleton is 40% to 50% lighter than competing devices and provides a modular design that can be assembled and disassembled for ease of use and transportation. The device is also smaller, with a slim profile and no bulky backpack components or footplates. A proprietary control interface allows for smooth operation that works in harmony with natural human movement and body position. The Parker exoskeleton is the only wearable device that incorporates a proven rehabilitation technology called functional electrical stimulation.

"To see patients who are otherwise confined to a wheelchair be given the opportunity to stand and walk again is truly rewarding and inspiring," said Dr. Ryan Farris, Parker's technology development leader for the device and co-inventor. "Under the direction of Dr. Michael Goldfarb at Vanderbilt, we were able to take advantage of the latest developments in sensor, actuation, and control technology to create a device that can greatly improve the quality of life for patients through regained mobility. As part of Parker, and through ongoing cooperation with Vanderbilt, it is now time to further develop, refine, and ready the exoskeleton for commercial availability."

The exoskeleton is currently being tested and refined through clinical research at the Shepherd Center in Atlanta, GA, one of the foremost rehabilitation hospitals in the U.S. Patient and clinician feedback on the device has been overwhelmingly positive, and the center has concluded that the device has the most promise as a rehabilitation and home device.

To read the Vanderbilt University Medical Center version of this announcement visit the center's Web site.

About Parker Hannifin
With annual sales exceeding $13 billion in fiscal year 2012, Parker Hannifin Corp. is the world's leading diversified manufacturer of motion and control technologies and systems, providing precision-engineered solutions for a wide variety of mobile, industrial, and aerospace markets. The company employs approximately 60,000 people in 48 countries around the world. Parker has increased its annual dividends paid to shareholders for 56 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index.

Suggested Articles

Renesas has introduced an evaluation and prototyping kit that will speed time-to-market to create secure end-to-end IoT cloud solutions for sensor-based…

MarketsandMarkets says the low-light imaging market is expected to grow from $10.04 billion in 2019 to $18.36 billion by 2024.

SiC can make medical devices more perceptive, it can make electronics more energy-efficient, and it can help sensors perform in higher temperatures.